07:55 AM EDT, 05/01/2025 (MT Newswires) -- ZYUS Life Sciences ( ZLSCF ) on Thursday said it has been issued a European patent for its cannabinoid-based Trichomylin softgel capsules, formulated specifically for pain management. The patent is effective until 2040.

Zyus also intends to raise up to $2 million via a non-brokered private placement of up to 3 million units at $0.66 each. Each unit is comprised of one share and half a warrant. Each 24-month warrant can buy a share at $0.94. The first tranche of the financing is expected to close on May 6.

Proceeds will be used for general corporate and working capital purposes.